Publication | Open Access

A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer

UrologyGenitourinary CancerMedicinePharmacologyRandomised Phase 2PharmacotherapyCastration-resistant Prostate CancerAntisense TherapyProstatic DiseaseOncologySurvivin Antisense Oligonucleotide